Residual contamination in antineoplastic drug packaging
Journal of Oncology Pharmacy Practice · 2023
DOI: 10.1177/10781552231151693 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology Pharmacy Practice, 2023. Verfasst von Luciana Stein E Silva und 7 weiteren Autor:innen. Beteiligte Einrichtung: Post Graduate Program in Health Sciences: Gynecology and Obstetrics, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Bra…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Occupational Exposure. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Fundo de Incentivo a Pesquisa (FIPE) da Diretoria de Pesquisa do Hospital de Clínicas de Porto Alegre.
Abstract (Originalsprache)
Introduction
The handling of antineoplastic drugs should follow strict supervision and safety rules to minimize the occupational exposure risks to professionals involved. The external surface contamination of drug vials is recognized as a health risk. So, our goal was to determine if there is residual contamination on the vials and containers surface of the antineoplastic drugs doxorubicin (DOX) and cyclophosphamide (CP).
Methods
A cross-sectional study was conducted. Samples were collected using a uniform sampling procedure on the inner surfaces of the packages/boxes and the outer surfaces of the vials. The analyzes were executed by high-performance liquid chromatography/mass spectrometry (UHPLC-MS/MS).
Results
A total of 209 samples were analyzed, 66 of CP and 143 of DOX. CP levels were detected in nine samples (13.63%), three were below the lower limit of quantification (LLQ) and the other six had contamination levels ranging from 1.24 to 28.04 ng/filter. DOX levels were detected in 36 samples (25.17%), two were below the LLQ and the others had levels between 1.32 and 664.84 ng/filter. The majority of samples with residual contamination were in vials (80.0%), however, boxes also showed contamination.
Conclusions
The results revealed the presence of residual contamination in the vials and packages of CP and DOX drugs. Although the residues found in each sample are small, special care should be taken in the handling and disposal of the antineoplastic drugs. The use of personal protective equipment is fundamental while handling the vials and packaging of cytotoxic drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Post Graduate Program in Health Sciences: Gynecology and Obstetrics, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
- Analytical Toxicology Laboratory, Feevale University, Novo Hamburgo, RS, Brazil.
- Graduate Program in Toxicology and Toxicological Analysis, Feevale University, Novo Hamburgo, RS, Brazil.
- Center for Intravenous Drug Preparation, Department of Pharmacy, Hospital de Clínicas Porto Alegre, Porto Alegre, RS, Brazil.
- Department of Gynecology and Obstetrics, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
ORCID-Profile: Luciana Stein E Silva, Carlos Alberto Yasin Wayhs, Sandro Luís Ribeiro Ness
Förderung
- Fundo de Incentivo a Pesquisa (FIPE) da Diretoria de Pesquisa do Hospital de Clínicas de Porto Alegre
Zitieren
APA
E Silva, L. S., Machado, C. D. S. B., Linden, R., Antunes, M. V., da Silva, L. C., Wayhs, C. A. Y., Capp, E., & Ness, S. L. R. (2023). Residual contamination in antineoplastic drug packaging. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552231151693
Vancouver
E Silva LS, Machado CDSB, Linden R, Antunes MV, da Silva LC, Wayhs CAY, et al. Residual contamination in antineoplastic drug packaging. Journal of Oncology Pharmacy Practice. 2023. doi:10.1177/10781552231151693
BibTeX
@article{ESilva2023,
author = {E Silva, Luciana Stein and Machado, Cibele da Silva Barbosa and Linden, Rafael and Antunes, Marina Venzon and da Silva, Laura Cé and Wayhs, Carlos Alberto Yasin and Capp, Edison and Ness, Sandro Luís Ribeiro},
title = {Residual contamination in antineoplastic drug packaging},
journal = {Journal of Oncology Pharmacy Practice},
year = {2023},
doi = {10.1177/10781552231151693}
}
EUVIMED